Article
Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project.
The American journal of clinical nutrition - 1 Jan 2003
Meleady Raymond, Ueland Per M, Blom Henk, Whitehead Alexander S, Refsum Helga, Daly Leslie E, Vollset Stein Emil, Donohue Cait, Giesendorf Belinda, Graham Ian M, Ulvik Arve, Zhang Ying, Bjorke Monsen Anne-Lise
Abstract excerpt
BACKGROUND: Homozygotes for the thermolabile mutation (TT genotype) of the methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20) enzyme have elevated plasma concentrations of the cardiovascular disease risk factor homocysteine, particularly if folate depleted. OBJECTIVE: We examined the relations between thermolabile MTHFR, plasma homocysteine, plasma folate, and vascular disease risk. DESIGN: This was a...
Topics
- Adult
- Cardiovascular Diseases
- Case-Control Studies
- Europe
- Female
- Folic Acid
- Genotype
- Homocysteine
- Humans
- Male
- Methylenetetrahydrofolate Reductase (NADPH2)
- Middle Aged
- Oxidoreductases Acting on CH-NH Group Donors